Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Dong-A ST Co., Ltd. clinical trials
The registry lists 122 studies whose lead sponsor is Dong-A ST Co., Ltd.. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
Keep track of what changes. Save the Dong-A ST Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Dong-A ST Co., Ltd..
- Dong-A ST Co., Ltd.122 studiesSame company
Something wrong?
Focus areas
Conditions Dong-A ST Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 122. Browse all 122 →
- A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional DyspepsiaRecruitingNCT07686679Phase 4
- Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short StatureRecruitingNCT04798690
- A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal AdenocarcinomaRecruitingNCT07481357Phase 1
- Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlNot yet recruitingNCT07239440Phase 2
- Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 DiabetesNot yet recruitingNCT07229534Phase 4
- Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult SubjectsNot yet recruitingNCT06993181Phase 1
- To Evaluate Effect of Food of DA-5222 in Healthy Adult SubjectsNot yet recruitingNCT06993168Phase 1
- Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06293651Phase 1/2
- Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult VolunteersNot yet recruitingNCT06616883Phase 1
- A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-RCompletedNCT07513649Phase 1
- A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult SubjectsCompletedNCT07633691Phase 1
- A Study to Evaluate the Food Effect on the Pharmacokinetics of DA-5223 in Healthy Adult SubjectsWithdrawnNCT07007520Phase 1
- Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult SubjectsCompletedNCT07239453Phase 1
- A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly ParticipantsCompletedNCT06391827Phase 1
- Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed StateCompletedNCT07342062Phase 1
- Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting StateCompletedNCT07297940Phase 1
- The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients With Acquired Lumbar Spinal StenosisCompletedNCT06654856
- Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlActive, not recruitingNCT06290349Phase 3
- Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed StateCompletedNCT07046715Phase 1
- A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and AdministrationCompletedNCT07139886Phase 2
- Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic GastritisCompletedNCT06151210Phase 3
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis WomenCompletedNCT05630768Phase 4
- A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult SubjectsCompletedNCT07027982Phase 1
- A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult SubjectsCompletedNCT07007533Phase 1
- Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic ControlCompletedNCT05743907Phase 4
- Clinical Trial of DA-5212 in Patients with Functional DyspepsiaCompletedNCT05842408Phase 3
- Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B PatientsCompletedNCT05957380Phase 4
- A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive BladderCompletedNCT05282069Phase 3
- A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010CompletedNCT05812417Phase 1
- Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy AdultsCompletedNCT05991401Phase 1
- Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy AdultsCompletedNCT05992428Phase 1
- Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT04785326Phase 3
- Phase 1 Clinical Trial of DA-5207 in Healthy AdultsCompletedNCT05127746Phase 1
- Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVDCompletedNCT04055883Phase 2
- Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed StateStatus unknownNCT05739916Phase 1
- Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fasting StateStatus unknownNCT05739903Phase 1
- Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed StateStatus unknownNCT05739877Phase 1
- Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting StateStatus unknownNCT05739851Phase 1
- A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.Status unknownNCT05506007Phase 1
- Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy SubjectsCompletedNCT04906109Phase 1
- Pharmacokinetics and Safety Profiles After Administration of DA-5218 and Co-administration of DA-5218-R1, DA-5218-R2 and DA-5218-R3 in Healthy Adult VolunteersStatus unknownNCT05449704Phase 1
- Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy SubjectsCompletedNCT05106205Phase 1
- Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult VolunteersCompletedNCT05132049Phase 1
- Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting StateCompletedNCT05098262Phase 1
- Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fed StateCompletedNCT05098886Phase 1
- Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)CompletedNCT04938752Phase 1
- Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed StateCompletedNCT05098275Phase 1
- Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting StateCompletedNCT05108571Phase 1
- Safety and Efficacy of DA-9805 for Parkinson's DiseaseCompletedNCT03189563Phase 2
- Bioequivalence Study Between "DA-5215 Tab" and "DA-5215-R Tab"Status unknownNCT05376085Phase 1